831 reports of this reaction
2.2% of all RIFAXIMIN reports
#6 most reported adverse reaction
AMMONIA INCREASED is the #6 most commonly reported adverse reaction for RIFAXIMIN, manufactured by Salix Pharmaceuticals, Inc.. There are 831 FDA adverse event reports linking RIFAXIMIN to AMMONIA INCREASED. This represents approximately 2.2% of all 37,072 adverse event reports for this drug.
Patients taking RIFAXIMIN who experience ammonia increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
AMMONIA INCREASED is a less commonly reported adverse event for RIFAXIMIN, but still significant enough to appear in the safety profile.
In addition to ammonia increased, the following adverse reactions have been reported for RIFAXIMIN:
AMMONIA INCREASED has been reported as an adverse event in 831 FDA reports for RIFAXIMIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
AMMONIA INCREASED accounts for approximately 2.2% of all adverse event reports for RIFAXIMIN, making it a notable side effect.
If you experience ammonia increased while taking RIFAXIMIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.